KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Operating Expenses (2016 - 2025)

Historic Operating Expenses for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $132.9 million.

  • CRISPR Therapeutics AG's Operating Expenses rose 2006.29% to $132.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $612.7 million, marking a year-over-year increase of 1448.16%. This contributed to the annual value of $503.9 million for FY2024, which is 1513.51% down from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Operating Expenses is $132.9 million, which was up 2006.29% from $230.2 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Operating Expenses peaked at $230.2 million during Q2 2025, and registered a low of $100.3 million during Q4 2024.
  • Its 5-year average for Operating Expenses is $148.7 million, with a median of $141.1 million in 2024.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 7103.66% in 2021, then crashed by 2743.89% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Operating Expenses (Quarter) stood at $158.6 million in 2021, then dropped by 17.06% to $131.5 million in 2022, then grew by 0.06% to $131.6 million in 2023, then dropped by 23.81% to $100.3 million in 2024, then surged by 32.58% to $132.9 million in 2025.
  • Its last three reported values are $132.9 million in Q3 2025, $230.2 million for Q2 2025, and $149.3 million during Q1 2025.